Transcatheter Pulmonary Valve Market By Technology (Balloon-Expanded Valves, Self-Expanded Valves); By Application / Indication (Pulmonary Valve Regurgitation, Pulmonary Valve Stenosis, Conduit Failure and Bioprosthetic Valve Dysfunction); By RVOT Anatomy (Conduit-Based RVOT, Native or Enlarged RVOT); By Raw Material (Biological / Tissue-Based Valves, Synthetic / Polymer-Based Valve Materials); By End User (Hospitals & Hybrid Operating Rooms, Cardiac Specialty Clinics and Congenital Heart Centers, Ambulatory Surgical Centers and Other Specialized Facilities); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Native-RVOT Expansion Puts TPV on a Wider Growth Track – (Updated On: 28th-Sep-2026)

The Global Transcatheter Pulmonary Valve Market was valued at USD 165.2 million in 2025 and is projected to reach USD 170.3 million by 2032, expanding at a CAGR of 11.2% during 2026–2032, according to Strategic Market Research.

 

The Transcatheter Pulmonary Valve (TPV) Market covers catheter-delivered prosthetic pulmonary valves and associated delivery systems used to restore pulmonary-valve function without conventional open-heart valve replacement. Transcatheter pulmonary valve replacement (TPVR) primarily serves congenital heart disease patients with pulmonary regurgitation, pulmonary stenosis, failing right ventricular outflow tract (RVOT) conduits, or deteriorating surgical bioprosthetic valves

 

The U.S. IMPACT registry recorded 4,513 balloon-expandable TPVR procedures with 95% acute procedural success, while major adverse events occurred in only 2.4% of procedures. In another international registry covering 840 SAPIEN 3 patients across 35 centers in 15 countries, successful valve implantation was achieved in 98.5% of cases. Notably, 50.7% of patients had native or surgically patched RVOT anatomy, showing that TPVR is expanding beyond patients with traditional surgical conduits.

 

Competition is also widening beyond established balloon-expandable systems such as Melody and SAPIEN 3. Self-expanding platforms including Venus P-Valve, Pulsta, and Med-Zenith PT-Valve are targeting larger and more variable RVOT anatomies. A 2025 clinical study involving 130 patients treated with the PT-Valve reported 98.5% procedural success, reflecting continued progress in devices designed for anatomies that are difficult to treat with conventional balloon-expandable valves.

 

Overall, the Transcatheter Pulmonary Valve Market is evolving from a niche conduit-focused procedure into a broader lifetime structural-heart treatment platform, supported by expanding native-RVOT eligibility, strong procedural success, improving long-term durability, and a growing adult congenital-heart population.

 

New Valve Platforms Open More Pulmonary Treatment Pathways

Treatment of pulmonary valve dysfunction depends on the patient's RVOT anatomy, severity of pulmonary regurgitation or stenosis, previous cardiac surgery, valve dimensions, and suitability for catheter-based intervention. The treatment landscape is increasingly shifting toward transcatheter pulmonary valve replacement (TPVR) because it can restore pulmonary-valve function without another open-heart operation.

Balloon-Expandable Transcatheter Pulmonary Valves

Medtronic Melody TPV remains one of the most established catheter-based treatment options for patients with a dysfunctional RVOT conduit or surgical bioprosthetic pulmonary valve. FDA labeling covers patients requiring intervention for at least moderate regurgitation and/or an RVOT mean gradient of 35 mmHg or higher.

Edwards SAPIEN 3 provides another major balloon-expandable treatment option for dysfunctional RVOT conduits and previously implanted surgical pulmonary valves. Its FDA indication includes patients with moderate-or-greater pulmonary regurgitation and/or an RVOT gradient of at least 35 mmHg. The FDA also approved Edwards' next-generation SAPIEN 3 pulmonic delivery system in January 2026, strengthening the commercial platform.

 

Self-Expanding TPV for Native and Surgically Repaired RVOTs

Medtronic Harmony TPV significantly expanded TPVR eligibility by treating patients with severe pulmonary regurgitation in a native or surgically repaired RVOT, including anatomies that may not contain a pre-existing conduit. FDA approval applies to pediatric and adult patients who would otherwise be clinically indicated for surgical pulmonary-valve replacement.

This treatment category is particularly important for patients with repaired Tetralogy of Fallot, where enlarged and irregular RVOT anatomy can make conventional balloon-expandable implantation difficult.

 

SAPIEN 3 With Alterra Adaptive Prestent

The Edwards SAPIEN 3 TPV with Alterra Adaptive Prestent provides a different solution for large native or surgically repaired RVOTs. Alterra creates a defined landing zone before placement of the balloon-expandable SAPIEN 3 valve. The FDA approved the combination in December 2021 for pediatric and adult patients with severe pulmonary regurgitation who require pulmonary-valve replacement.

 

Valve-in-Valve Treatment

Patients with a failing previously implanted surgical bioprosthetic pulmonary valve may undergo transcatheter valve-in-valve replacement rather than another surgical valve operation. Melody and SAPIEN platforms are established options in this setting. This creates an important recurring treatment opportunity as congenital-heart patients may require multiple pulmonary-valve interventions over their lifetime.

 

Surgical Pulmonary Valve Replacement

Open surgical pulmonary valve replacement remains important when anatomy is unsuitable for catheter-based devices, when additional cardiac defects require correction, or when reconstruction of the RVOT or pulmonary arteries is required. Surgery therefore remains complementary to TPVR rather than being completely displaced by catheter-based systems.

 

Six Market Segments Map the Next TPV Revenue Shift

By Technology — Established Balloon Platforms Meet the Native-RVOT Expansion Wave

Leading Subsegment – Balloon-Expanded Valves

Balloon-expandable valves dominate the technology segment of the Transcatheter Pulmonary Valve Market, accounting for an estimated 64% share and USD 105.7 million in 2025 revenue. The segment is forecast to grow at a CAGR of 8.6% from 2026 to 2032. Their precise deployment, strong radial force, and suitability for dysfunctional RVOT conduits and failing bioprosthetic valves support broad clinical use. Expanding application in selected native and patched RVOT anatomies is further strengthening demand for SAPIEN and Myval valve systems globally.

Fastest-Growing Subsegment – Self-Expanded Valves

Self-expanding valves represent about 36% of the Transcatheter Pulmonary Valve Market in 2025, equivalent to USD 59.5 million, and are forecast to post the fastest technology CAGR of nearly 16.0% through 2032. Their growth is supported by wider use in patients with large, dilated, or irregular right ventricular outflow tracts, where balloon-expandable valves may be unsuitable. Nitinol-based designs such as VenusP-Valve and PULSTA improve anchoring, expand treatment eligibility, and provide a minimally invasive option for pulmonary regurgitation following congenital repair.

 

By Application — Pulmonary Regurgitation Defines the Largest Revenue Pool

Leading and Fastest-Growing Subsegment– Pulmonary Valve Regurgitation

Pulmonary valve regurgitation accounts for approximately 58% of Transcatheter Pulmonary Valve Market revenue, valued at USD 95.8 million in 2025, and is projected to expand at a 12.5% CAGR during 2026–2032. Chronic pulmonary regurgitation remains a major indication for transcatheter pulmonary valve replacement, particularly among patients with repaired congenital heart disease and dysfunctional RVOT conduits. Progressive right ventricular dilation and volume overload increase the need for valve intervention, supporting sustained demand for minimally invasive transcatheter pulmonary valve procedures.

 

By RVOT Anatomy — Native RVOT Treatment Becomes the Key Expansion Opportunity

Leading Subsegment – Conduit-Based RVOT

Conduit-based RVOT procedures account for approximately 57% of the Transcatheter Pulmonary Valve Market, generating USD 94.2 million in 2025, and are projected to expand at an 8.1% CAGR through 2032. Surgically implanted conduits provide a defined landing zone for transcatheter pulmonary valves such as Melody and SAPIEN. As these conduits progressively calcify, narrow, or develop regurgitation, TPVR offers a less invasive alternative to repeat open-heart surgery, supporting sustained procedural demand among congenital heart disease patients requiring RVOT reintervention.

Fastest-Growing Subsegment – Native or Enlarged RVOT

Native or Enlarged RVOT segment accounted for approximately 43% share of the the Transcatheter Pulmonary Valve Market  and USD 71.0 million in 2025 revenue and is projected to expand at a 15.3% CAGR through 2032. Growth is supported by increasing use of dedicated self-expanding and large-diameter valve systems for patients with widened, compliant RVOT anatomy after congenital heart defect repair. These devices broaden TPVR eligibility and reduce the need for repeat open-heart surgery while supporting effective pulmonary valve function restoration.

 

By Raw Material — Biological Tissue Maintains Commercial Leadership

Leading Subsegment – Biological/Tissue-Based Valves

Biological valves dominate the Transcatheter Pulmonary Valve Market with approximately 91% share and USD 150.3 million in 2025 revenue, expanding at an estimated 10.8% CAGR through 2032. Their leadership reflects the widespread use of bovine, porcine, and other tissue-based leaflets in catheter-delivered pulmonary valves. These valves combine strong hemocompatibility with low thrombotic risk and generally avoid lifelong anticoagulation. Their flexible tissue structure also supports balloon-expandable and self-expanding delivery systems, making them well suited for minimally invasive pulmonary valve replacement.

Fastest-Growing Subsegment – Synthetic and Next-Generation Valve Materials

Synthetic and polymer-based valves account for an estimated 9% of the Transcatheter Pulmonary Valve Market, representing about USD 14.9 million in 2025, and are projected to grow at nearly 15.2% CAGR. Their adoption is supported by thinner leaflet designs, smaller catheter profiles, lower manufacturing costs, and reduced reliance on animal tissue. Materials such as ePTFE, modified polyurethanes, and styrenic elastomers are gaining attention for improved durability, calcification resistance, hemocompatibility, and suitability for pediatric transcatheter valve applications and future TPV development.

 

By End User — High-Acuity Cardiac Centers Control TPVR Adoption

Leading Subsegment – Hospitals & Hybrid Operating Rooms

Hospitals and hybrid operating rooms (ORs) dominate the Transcatheter Pulmonary Valve Market, accounting for approximately 78% of revenue, or USD 128.9 million in 2025, and are projected to expand at a 10.8% CAGR through 2032. Their leadership reflects the concentration of TPVR procedures in advanced cardiac centers equipped with fixed fluoroscopy, multimodal imaging, congenital heart specialists, and immediate surgical backup. Hybrid ORs also support complex RVOT anatomies by enabling combined surgical and transcatheter procedures within a single controlled environment.

Fastest-Growing Subsegment – Ambulatory and Specialized Procedure Facilities

Ambulatory surgical centers and other specialized facilities account for approximately 4% of the Transcatheter Pulmonary Valve Market, representing nearly USD 6.6 million in 2025 revenue, and are projected to expand at a 13.8% CAGR during 2026–2032. Their direct role in TPVR implantation remains limited, as procedures require hospital-based cardiac surgery backup and multidisciplinary heart teams. Growth instead comes from specialized outpatient imaging, congenital heart disease monitoring, pre-procedural assessment, post-procedure follow-up, and cardiac rehabilitation services supporting the broader TPVR care pathway.

 

By Geography — North America Leads While Asia-Pacific Builds a Domestic Innovation Base

Leading Region – North America

North America leads the Transcatheter Pulmonary Valve Market with an estimated 46% share, representing USD 76.0 million in 2025 revenue, and is projected to grow at a 9.6% CAGR through 2032. Regional demand is supported by the growing pool of patients with congenital heart defects requiring pulmonary valve replacement, particularly those with failed right ventricular outflow tract (RVOT) conduits and prior surgical repairs. Increasing adoption of TPVR procedures using catheter-based valve systems, expanding congenital cardiology programs, and rising preference for repeat minimally invasive interventions are strengthening market growth across the United States and Canada.

Fastest-Growing Region – Asia-Pacific

Asia-Pacific accounts for approximately 21% of the Transcatheter Pulmonary Valve Market, valued at USD 34.7 million in 2025, and is projected to record the fastest regional CAGR of around 15.7% during 2026–2032. Regional TPV demand is increasing as a growing population of congenital heart disease patients with previously implanted surgical conduits requires pulmonary valve replacement and long-term RVOT management. Rising availability of catheter-based interventions, expansion of congenital cardiology programs, and increasing adoption of transcatheter pulmonary valve replacement procedures across specialized cardiac centers are strengthening market growth across Asia-Pacific.

 

Established TPV Platforms Define a Concentrated Competitive Field

Medtronic — Broadest Dedicated Pulmonary-Valve Portfolio

Medtronic holds one of the strongest positions in the Transcatheter Pulmonary Valve Market through its Melody TPV and Harmony TPV systems, giving the company coverage across both traditional conduit-based and native-RVOT patients. Melody was the first commercially approved transcatheter pulmonary valve and has treated more than 18,000 patients globally since 2006. Harmony extends Medtronic's reach into patients with severe pulmonary regurgitation and a native or surgically repaired RVOT, an anatomy historically treated with repeat open-heart surgery. By January 2025, Medtronic reported that more than 2,200 patients had received Harmony, and the system subsequently received European CE marking. Longer-term evidence is strengthening this position: at three years, all TPV22 recipients and 96% of TPV25 recipients had mild-or-less pulmonary regurgitation in a pooled Harmony cohort.

 

Edwards Lifesciences — SAPIEN Platform Expands Across Multiple RVOT Anatomies

Edwards Lifesciences is another central TPV competitor through the SAPIEN 3 transcatheter valve, dedicated pulmonic delivery system, and Alterra Adaptive Prestent. Alterra creates a standardized landing zone for the SAPIEN 3 valve in patients with large native or surgically repaired RVOTs, substantially widening the addressable patient group beyond conventional conduits. The FDA approved the SAPIEN 3 with Alterra system in December 2021, followed by approval of Edwards' next-generation SAPIEN 3 pulmonic delivery system in January 2026. An international SAPIEN 3 registry covering 840 patients across 35 centers in 15 countries recorded 98.5% successful implantation, while 50.7% of patients had native or patched RVOT anatomy. Three-year Alterra/SAPIEN evidence also reported 97.3% freedom from reintervention and mild-or-less pulmonary regurgitation in 93.3% of patients.

 

Venus Medtech — Building a Global Position in Self-Expanding Native-RVOT Valves

Venus Medtech has emerged as an important self-expanding TPV manufacturer through the VenusP-Valve, designed particularly for patients with enlarged native RVOTs. VenusP-Valve became the first self-expanding TPVR system approved in both Europe and China, receiving European CE MDR marking and Chinese NMPA approval in 2022. The company reported by 2024 that the device had regulatory approval across more than 50 countries, while a U.S. pivotal IDE program was initiated to support potential FDA registration. Independent long-term evidence has also strengthened the platform: a 2026 study of 58 attempted implantations reported 96.6% successful implantation, with no early or late deaths and no severe pulmonary regurgitation during follow-up extending beyond five years. Another five-year study reported 98% freedom from reintervention among VenusP-Valve patients.

 

Emerging TPV Platforms Broaden the Competitive Field

• TaeWoong Medical — PULSTA Valve: Develops the self-expanding PULSTA TPV for native RVOT dysfunction; a South Korean post-marketing study of 299 patients achieved 99% procedural success, with no deaths during follow-up.

• Med-Zenith — PT-Valve: Develops the PT-Valve, a self-expanding transcatheter pulmonary valve aimed at enlarged native RVOT anatomy; the company identifies it as a major congenital-heart product currently progressing through Chinese regulatory review.

 

Analyst View: Native-RVOT Reach Sets the Growth Pace

The Transcatheter Pulmonary Valve Market is moving beyond traditional conduit-based interventions toward treatment of larger native and surgically repaired RVOT anatomies. Balloon-expandable platforms such as Melody and SAPIEN continue to support the established procedure base, while self-expanding systems such as Harmony, VenusP-Valve, and PULSTA are widening patient eligibility. The next phase of market growth will be shaped by native-RVOT treatment, longer valve durability, and reduced need for repeat open-heart surgery. 

 

Transcatheter Pulmonary Valve Market Report Coverage at a Glance

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 165.2 Million
Revenue Forecast in 2032	USD 170.3 Million
Overall Growth Rate	CAGR of 11.2% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026–2032)
Segmentation	By Technology, By Application / Indication, By RVOT Anatomy, By Raw Material, By End User, By Geography
By Technology	Balloon-Expanded Valves, Self-Expanded Valves
By Application / Indication	Pulmonary Valve Regurgitation, Pulmonary Valve Stenosis, Conduit Failure and Bioprosthetic Valve Dysfunction
By RVOT Anatomy	Conduit-Based RVOT, Native or Enlarged RVOT
By Raw Material	Biological / Tissue-Based Valves, Synthetic / Polymer-Based Valve Materials
By End User	Hospitals & Hybrid Operating Rooms, Cardiac Specialty Clinics and Congenital Heart Centers, Ambulatory Surgical Centers and Other Specialized Facilities
By Geography	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, Germany, France, Netherlands, China, India, South Korea, Japan, Brazil, Mexico, UAE, Saudi Arabia, South Africa
Market Drivers	expanding native-RVOT eligibility, strong procedural success, improving long-term durability, and a growing adult congenital-heart population
Customization Option	Available upon request